WHWK earnings analysis
What we found in WHWK's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Whitehawk Therapeutics reported no revenue in Q1 2026, missing estimates following the $7.1 million achieved in Q1 2025. The company faced a significant net loss of $22.2 million in the current quarter compared to a net income of $73.0 million from the previous year, prompting concerns over cash reserves which now stand at $123 million. Management is focused on advancing clinical trials for its ADC therapies despite ongoing financial challenges.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Zero Revenue in Q1 2026
- Revenue for Q1 2026 was $0, down from $7.1 million in Q1 2025, highlighting significant revenue loss.
- Increased R&D Spending
- R&D expenses rose to $17.2 million in Q1 2026 from $8.8 million in Q1 2025, reflecting investment in developing ADC therapies.
- Cash Reserves Adequate Until 2028
- Cash, cash equivalents, and short-term investments total $123 million, expected to fund operations until 2028.
- Management's Commitment to Trials
- Management is focused on advancing Phase 1 trials for ADC therapies HWK-007 and HWK-016, with initial data expected in 1H 2027.
- Decrease in SG&A Expenses
- Selling, general, and administrative expenses decreased to $6.3 million in Q1 2026, down from $12.8 million in Q1 2025.
- Substantial Net Loss Reported
- Net loss was $22.2 million in Q1 2026 compared to net income of $73 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Net Loss
- Reporting a net loss of $22.2 million in Q1 2026, compared to a net income of $73 million in the same quarter last year.
- Dependence on Clinical Trials
- Failure to achieve positive results in Phase 1 trials for HWK-007 and HWK-016 may hinder future revenue potential.
- Ongoing Cash Burn
- Cash reserves at $123 million may not suffice if R&D and operational costs remain high, risking the ability to fund future development.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.32
What they said about what is next.
Outlook deferred to future reports; focus on trial progression for ADC therapies.
The filing reads worse than the one before it.
What came before.
- 10-K · March 12, 2026
- Whitehawk has completed a strategic pivot from a small commercial franchise (FYARRO) to an in‑licensed, three‑program next‑generation ADC portfolio (PTK7, MUC16, SEZ6) under the December 2024 WuXi License Agreement and…
- 10-Q · November 6, 2025
- Whitehawk reported Q3 2025 product revenue of $0 (down from $7.212 million in Q3 2024) after the FYARRO divestiture, producing a Q3 net loss of $(17.746) million and basic EPS of $(0.26). The company materially…
- 10-K · March 28, 2025
- Whitehawk pivoted from a single-product commercial model (FYARRO) toward an in-licensed, next‑generation ADC portfolio (three ADC Therapies) acquired under the WuXi License Agreement with IND filings expected in the…
- 10-K · March 13, 2024
- Aadi Bioscience (WHWK) commercialized FYARRO following FDA approval (Nov 22, 2021) and launched in the U.S. on Feb 22, 2022. Net product sales increased to $24.4 million in 2023 from $15.2 million in 2022, while the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing WHWK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever